CDK2 and breast cancer: In terms of patient outcome, there was a significant association between high nuclear CDK2 and poor breast cancer-specific survival (BCSS) (p = 0.006) (Figure 1D), while cytoplasmic CDK2 did not show association with the patient outcome (Supplementary Figure S1B).